ACTG2 | Actin, gamma 2, smooth muscle, enteric | | | | |
|
| | Tissue enhanced | 0 |
ADAMTSL5 | ADAMTS-like 5 | | | | |
|
| | Tissue enhanced | 0 |
ASPN | Asporin | | | | |
|
| Nucleus but not nucleoli Vesicles | Tissue enhanced | 0 |
BAG2 | BCL2-associated athanogene 2 | | | | |
|
| Nucleus but not nucleoli | Tissue enhanced | 0 |
C3orf70 | Chromosome 3 open reading frame 70 | | | | |
|
| Cytoplasm | Tissue enhanced | 0 |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | | | | |
|
| | Tissue enhanced | 0 |
CCDC80 | Coiled-coil domain containing 80 | | | | |
|
| | Tissue enhanced | 0 |
CHURC1-FNTB | CHURC1-FNTB readthrough | | | | | N/A |
| | Tissue enhanced | 0 |
CILP | Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase | | | | |
|
| | Tissue enhanced | 0 |
CNN1 | Calponin 1, basic, smooth muscle | | | | |
|
| Cytoskeleton (Actin filaments) | Tissue enhanced | 0 |
CNTNAP1 | Contactin associated protein 1 | | | | |
|
| Nucleus but not nucleoli | Tissue enhanced | 0 |
COL3A1 | Collagen, type III, alpha 1 | | | | |
|
| | Tissue enhanced | 0 |
COL4A6 | Collagen, type IV, alpha 6 | | | | | |
| | Tissue enhanced | 0 |
CPXM2 | Carboxypeptidase X (M14 family), member 2 | | | | |
|
| | Tissue enhanced | 0 |
DPYSL3 | Dihydropyrimidinase-like 3 | | | | |
|
| Cytoplasm | Tissue enhanced | 0 |
FAM83D | Family with sequence similarity 83, member D | | | | |
|
| | Tissue enhanced | 0 |
FBXL22 | F-box and leucine-rich repeat protein 22 | | | | |
|
| | Tissue enhanced | 0 |
FBXO32 | F-box protein 32 | | | | | |
| Nucleus but not nucleoli Cytoplasm | Tissue enhanced | 0 |
GAL | Galanin/GMAP prepropeptide | | | | |
|
| | Tissue enhanced | 0 |
GAL3ST3 | Galactose-3-O-sulfotransferase 3 | | | | | |
| | Tissue enhanced | 0 |
GALR2 | Galanin receptor 2 | | | | |
|
| | Tissue enhanced | 0 |
GJC1 | Gap junction protein, gamma 1, 45kDa | | | | | |
| | Tissue enhanced | 0 |
GLRA4 | Glycine receptor, alpha 4 | | | | |
|
| | Tissue enhanced | 0 |
GPR161 | G protein-coupled receptor 161 | | | | |
|
| | Tissue enhanced | 0 |
GREM1 | Gremlin 1, DAN family BMP antagonist | | | | |
|
| | Tissue enhanced | 0 |
GRM7 | Glutamate receptor, metabotropic 7 | | | | |
|
| Cytoplasm | Tissue enhanced | 0 |
GUCY1A2 | Guanylate cyclase 1, soluble, alpha 2 | | | | |
|
| | Tissue enhanced | 0 |
HAND1 | Heart and neural crest derivatives expressed 1 | | | | |
|
| Nucleus Nuclear membrane | Tissue enhanced | 0 |
HOXA10 | Homeobox A10 | | | | |
|
| Nucleus but not nucleoli | Tissue enhanced | 0 |
HOXC8 | Homeobox C8 | | | | |
|
| Nucleus but not nucleoli Cytoskeleton (Microtubules) | Tissue enhanced | 0 |
HOXD10 | Homeobox D10 | | | | | |
| | Tissue enhanced | 0 |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | | | | |
|
| Nucleus but not nucleoli | Tissue enhanced | 0 |
IL20 | Interleukin 20 | | | | |
|
| | Tissue enhanced | 0 |
ITGA11 | Integrin, alpha 11 | | | | |
|
| | Tissue enhanced | 0 |
KCNE4 | Potassium voltage-gated channel, Isk-related family, member 4 | | | | |
|
| | Tissue enhanced | 0 |
KCNMA1 | Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | | | | |
|
| | Tissue enhanced | 0 |
KCNMB1 | Potassium large conductance calcium-activated channel, subfamily M, beta member 1 | | | | |
|
| | Tissue enhanced | 0 |
KLHL13 | Kelch-like family member 13 | | | | |
|
| | Tissue enhanced | 0 |
LEFTY2 | Left-right determination factor 2 | | | | |
|
| | Tissue enhanced | 0 |
LINGO2 | Leucine rich repeat and Ig domain containing 2 | | | | |
|
| Nucleus Nucleoli Cytoplasm | Tissue enhanced | 0 |
LONRF2 | LON peptidase N-terminal domain and ring finger 2 | | | | | |
| Nucleus | Tissue enhanced | 0 |
MFAP5 | Microfibrillar associated protein 5 | | | | |
|
| | Tissue enhanced | 0 |
MOXD1 | Monooxygenase, DBH-like 1 | | | | |
|
| | Tissue enhanced | 0 |
MYH11 | Myosin, heavy chain 11, smooth muscle | | | | |
|
| Plasma membrane Cytoplasm | Tissue enhanced | 0 |
NRXN3 | Neurexin 3 | | | | |
|
| | Tissue enhanced | 0 |
P4HA3 | Prolyl 4-hydroxylase, alpha polypeptide III | | | | |
|
| | Tissue enhanced | 0 |
PCDH20 | Protocadherin 20 | | | | | |
| | Tissue enhanced | 0 |
PI15 | Peptidase inhibitor 15 | | | | |
|
| | Tissue enhanced | 0 |
PTGES3L-AARSD1 | PTGES3L-AARSD1 readthrough | | | | |
|
| | Tissue enhanced | 0 |
RSPO3 | R-spondin 3 | | | | |
|
| | Tissue enhanced | 0 |